NCT04921241View on ClinicalTrials.gov

In Utero Exposure to SARS-CoV-2 (COVID-19) and Cardiovascular and Metabolic Endpoints in Early Life

CompletedOBSERVATIONAL
Enrollment

86

Participants

Timeline

Start Date

June 8, 2021

Primary Completion Date

September 28, 2022

Study Completion Date

January 1, 2024

Conditions
In Utero SARS-CoV-2 Exposure
Interventions
OTHER

In Utero Exposure to SARS-CoV-2

Born to mother with SARS-CoV-2 infection during pregnancy

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER